Compare AEIS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEIS | CORT |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 9.7B |
| IPO Year | 1996 | 2001 |
| Metric | AEIS | CORT |
|---|---|---|
| Price | $224.53 | $80.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $415.00 | $141.00 |
| AVG Volume (30 Days) | 573.7K | ★ 869.8K |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 168.53 | N/A |
| EPS | ★ 2.86 | 0.09 |
| Revenue | $453,095,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $34.79 | $50.53 |
| Revenue Next Year | $24.79 | $46.23 |
| P/E Ratio | ★ $77.66 | $903.72 |
| Revenue Growth | ★ 38.39 | 12.79 |
| 52 Week Low | $187.71 | $28.66 |
| 52 Week High | $397.44 | $126.38 |
| Indicator | AEIS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 23.20 |
| Support Level | $210.50 | $77.38 |
| Resistance Level | $350.63 | $122.93 |
| Average True Range (ATR) | 11.99 | 5.62 |
| MACD | -1.09 | -3.25 |
| Stochastic Oscillator | 28.11 | 3.22 |
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.